

Please send your comments to;

ipmn2022kyoto@gmail.com

Please visit HP of IAP 2022.

IAP & JPS 2022
JOINT CONGRESS OF
THE 26TH MEETING OF INTERNATIONAL ASSOCIATION OF
PANCREATOLOGY (IAP) AND
THE 53RD ANNUAL MEETING OF JAPAN PANCREAS SOCIETY (JPS)



HOME

General Information

Program

Registration & Abstract ▾

Contact & Link ▾

Reunion

Towards a New Horizon

DATE : 7 [THU] - 9 [SAT] JULY, 2022

VENUE : KYOTO INTERNATIONAL CONFERENCE CENTER

THE 26TH IAP
CONGRESS PRESIDENT : YOSHIFUMI TAKEYAMA, MD, PhD
PROFESSOR AND CHAIRMAN, DEPARTMENT OF SURGERY,
KINDAI UNIVERSITY FACULTY OF MEDICINE

THE 53RD JPS
CONGRESS PRESIDENT : KYOICHI TAKAORI, MD, PhD
PRESIDENT, NAGAHAMA CITY HOSPITAL



Group 1; Revision of HRS and WF

High Risk Stigmata (HRS) + Worrisome features (WF)

- Diagnostic modality

CT and MRI/MRCP → CT and MRI/MRCP (+ EUS, if applicable) ?

HRS


- Enhanced MN $\geq 5\text{mm}$ → $\geq 10\text{mm}$?
- MPD diameter $\geq 10\text{mm}$ → dilated MPD as WF ?
- Positive results of EUS-FNA cytology ?

WF


- Multiple WFs

Surgery recommend, when ≥ 2 WFs ?

Application of Nomogram ?



Group 2; Surveillance of non-resected IPMN






Until when?

How to care concomitant PDAC?

Group 3; Surveillance after resection of IPMN

Possible “clinically significant lesions” in the “remnant pancreas” even after resection of “non-invasive IPMN”



Risk factors

- HGD (initial IPMN)
- Family history of panc. ca
- Margin positive

Image of significant lesions

- Solid mass
- MPD dilation
- Growth of cystic lesion

Group 4; Pathological aspects

- Usefulness of **morphological types** of IPMN for diagnosis, treatment, prediction of prognosis, and assessing risk of recurrence including concomitant carcinoma.
 - Associated with prognosis, and provide additional discrimination beyond grade of dysplasia.
- Handling of the intraductal oncocytic papillary neoplasm (IOPN), formerly an **oncocytic** type IPMN.
 - IOPN should be separated from IPMN.
- Whether it is affordable or relevant to use “**carcinoma in situ**” as a synonymous to IPMN with **HGD**.
 - Carcinoma in situ = HGD. To use the term “Malignant” IPMN is not recommended.
- Usefulness of **molecular analysis of IPMN tissues** for diagnosis, treatment, and surveillance of IPMN.
 - *GNAS/KRAS* mutations are not associated with prognosis, and more data is needed for other markers.
- Application of knowledge for development of **carcinoma associated/concomitant with IPMN** on clinical practice.
 - IPMC and concomitant PDAC should be distinguished pathologically.
- Application and values of **frozen section** diagnosis.
 - LGD does not justify completion pancreatectomy, while additional resection for HGD/Invasive IPMN.
- Appropriate pathology reporting for IPMN including determination of **T-factor**.
 - Size of invasive component should be measured.
- Application and values of **cytological analysis** of cyst fluid and/or pancreatic juice.
 - Add value to risk assessment, important for clinical management .

Group 5; Markers in cystic fluid

CQ1- Can cyst fluid molecular markers differentiate IPMNs/MCNs from other types of cysts?

Recommendation:

Molecular markers can be used when the diagnosis of a pancreatic cyst is unclear and will alter surveillance.

CQ2- Can cyst fluid molecular markers distinguish IPMNs/MCNs with low-grade dysplasia from high-grade dysplasia or PDAC?

Recommendation:

TP53, *SMAD4*, *CDKN2A* and *PIK3CA* mutations are useful in identifying the presence of high-grade dysplasia and PDAC.